694 related articles for article (PubMed ID: 33304317)
1. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
3. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.
Gajate P; Alonso-Gordoa T; Martínez-Sáez O; Molina-Cerrillo J; Grande E
Clin Transl Oncol; 2018 May; 20(5):561-569. PubMed ID: 29124519
[TBL] [Abstract][Full Text] [Related]
5. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
7. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
[TBL] [Abstract][Full Text] [Related]
8. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
11. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
12. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
[TBL] [Abstract][Full Text] [Related]
13. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
15. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
[TBL] [Abstract][Full Text] [Related]
16. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
18. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
19. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F; Berg E; Grass I; Freitag H; Kaemmerer D; Lewens F; Christen F; Arsenic R; Altendorf-Hofmann A; Kunze A; Sänger J; Knösel T; Siegmund B; Hummel M; Grabowski P
Oncotarget; 2015 Apr; 6(10):8185-99. PubMed ID: 25797272
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]